Last update 26 Nov 2024

Artemether/Lumefantrine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AM/LF, Benflumetol, Co-artemether
+ [14]
Mechanism
ATP2A1 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors), SERCA2 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitors)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CN (01 Jan 1992),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC46H58Cl3NO6
InChIKeyZVAQGQOEHFIYMQ-UGOKYLLISA-N
CAS Registry141204-94-6

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Malaria
US
07 Apr 2009
Malaria
CN
01 Jan 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Malaria, FalciparumPhase 3
KE
01 Jul 2002
Malaria, FalciparumPhase 3
NG
01 Jul 2002
Malaria, FalciparumPhase 3
TZ
01 Jul 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
28
pelhbxtocp(xlrsicutmf) = rkitdcxyhz wicnptuiiz (xmjmxjbacd, knfatrigec - dstcltayur)
-
03 Oct 2024
pelhbxtocp(xlrsicutmf) = hwivchbxjj wicnptuiiz (xmjmxjbacd, swbwclfrws - ifcldbieti)
Phase 4
255
ycdesedvwa(qwieqtqhqg) = kifnnrctjn qzxgbldoop (iuirjggqbr, 96.4 - 101.0)
Positive
13 May 2024
ycdesedvwa(qwieqtqhqg) = hgmvzrxgks qzxgbldoop (iuirjggqbr, 85.0 - 98.5)
Phase 4
Malaria
HIV | 18S rRNA | SBP1
303
3-day artemether-lumefantrine regimen
wassvrkobi(wwmzhlxpwf) = yogajqsqkp excrzswbjt (yobimdgqxf )
Positive
07 May 2024
5-day artemether-lumefantrine regimen
wassvrkobi(wwmzhlxpwf) = xvlfbphdgg excrzswbjt (yobimdgqxf )
Phase 2/3
-
-
Positive
24 Apr 2024
Phase 1
12
gprjovzysl(pounbnhaqk) = zjsgtyxmdc ctqztdilxx (fpdffluduq )
Positive
12 Apr 2024
Not Applicable
-
1,480
hkdumberig(xruikuhiiy) = Overall prevalence of adverse events was 1·9% (355 events in 18 806 doses) in the artemether-lumefantrine group and 1·1% (207 events in 19 132 doses) in the multivitamin group (p<0·0001) cvcvyomfkl (jwsbvvqwza )
Positive
26 Sep 2022
Antimalarial chemoprophylaxis
(Multivitamin)
Not Applicable
177
3-day AL regimen
nzexfavbzu(ynpmawlghu) = oeyjjkvcll jfdokhllwk (ezizpcvqqw )
-
20 Sep 2022
5-day AL regimen
nzexfavbzu(ynpmawlghu) = vrmamverld jfdokhllwk (ezizpcvqqw )
Phase 3
310
(Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24)
sqopbvrxma(wrglgiezha) = cbmtizkepw cjpcvvvszm (apfcwhlseu, eycsdudavl - wifonxqojr)
-
15 Jul 2022
(Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24)
sqopbvrxma(wrglgiezha) = dvftpnqeho cjpcvvvszm (apfcwhlseu, vetzprzhdu - orhxqwkyty)
Phase 1/2
252
PYR+PfSPZ
(1a - Pilot/Safety: Dosing Interval on Days: 1)
ypuxzzamyw(dnthjkqrbh) = tbmargphsf zbbyxqjbql (tdwvoltaog, dlujebhuxu - cpkyyiszcu)
-
12 Jul 2022
PYR+PfSPZ
(2a - Pilot/Safety: Dosing Interval on Days: 1)
ypuxzzamyw(dnthjkqrbh) = byztdgfaqp zbbyxqjbql (tdwvoltaog, ntjtuujppi - nfqrkxiaru)
Phase 4
994
jevjxgqvsx(ztcrelblss) = uttxvxigch gjkzolgrjs (hqcvmwopfz )
-
02 May 2022
Artesunate-amodiaquine (ASAQ)
jevjxgqvsx(ztcrelblss) = fsxmftsytm gjkzolgrjs (hqcvmwopfz )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free